MC2 Biotek

MC2 Therapeutics is a commercial-stage pharmaceutical company focused on developing and commercializing novel topical therapies for chronic inflammatory conditions, with a primary focus on dermatology and ophthalmology. The company utilizes its proprietary PAD Technology, a formulation platform designed to improve the solubility, stability, and skin penetration of active ingredients while providing a superior patient experience. Its lead product, Wynzora Cream, is FDA-approved for the treatment of plaque psoriasis and is marketed through partnerships with major pharmaceutical firms like Sun Pharma and Almirall. MC2 Therapeutics continues to advance a pipeline of candidates targeting conditions such as uremic pruritus, rosacea, and dry eye disease. The company's approach combines established active pharmaceutical ingredients with innovative delivery systems to address unmet needs in topical medicine.